Wechselwirkungen · Tarceva
Tarceva 25 mg film-coated tablets Tarceva 100 mg film-coated tablets Tarceva 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-114472 · Präparat HOS-094097
When erlotinib was co-administered with ciprofloxacin, a moderate CYP1A2 inhibitor, the erlotinib exposure [AUC] increased significantly by 39%, while no statistically significant change in Cmax was found. Similarly, the exposure to the active metabolite increased by about 60% and 48% for AUC and Cmax, respectively. The clinical relevance of this increase has not been established. Caution should be exercised when ciprofloxacin or potent CYP1A2 inhibitors (e.g. fluvoxamine) are combined with erlotinib. If adverse reactions related to erlotinib are observed, the dose of erlotinib may be reduced.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ciprofloxacin (HOS-085177) fluvoxamine (HOS-085908)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T14:10:00Z · SHA-256 4f9c738a5861ce6d74c31277709e30968e275c29015450902926409dd5330a31 · Passage 57935e94c44852635c62575abef0f7dba7ae979c3454a5110edcb18b455b45c8 · Zeichen 389–989 im Abschnitt